Avaliação de genótipos de feijoeiro comum, do grupo carioca, na época das águas, em Uberlândia-MG

O feijoeiro comum (Phaseolus vulgares L.) é cultivado em diferentes sistemas de produção e por pequenos e grandes produtores. O grupo carioca chega a ocupar 85% do mercado brasileiro. O melhoramento do feijoeiro constitui a forma eficiente de buscar cultivares mais adaptados aos diferentes ambientes a que são submetidos. O presente trabalho teve como objetivo avaliar o comportamento de diferentes genótipos de feijoeiro comum do grupo carioca, na época das águas. O experimento foi conduzido na Fazenda Experimental Água Limpa, pertencente à Universidade Federal de Uberlândia (UFU), no município de Uberlândia-MG, utilizando o delineamento experimental de blocos casualizados com 26 tratamentos e três repetições, totalizando 78 parcelas. Cada parcela foi constituída por quatro linhas de quatro metros de comprimento, com um espaçamento de 0,5m, totalizando 8,0m² de área total e 4,0m² de área útil, haja vista que, apenas as duas linhas centrais foram colhidas e utilizadas para as avaliações, no período compreendido entre 29/12/2008 a 31/03/2009. Os tratamentos foram representados pelos genótipos: BRS COMETA, CNFC 10720, VC-15, RP-2, CVIII-85-11, BRSMG MAJESTOSO, PÉROLA, BP-31, VC-13, VC-14, VC-16, CVIII-39-24, CNFC 10764, MAII-2, BRSMG PIONEIRO, RP-1, MAII-22, BRS 9461, MAII-16, BRSMG TALISMÃ, CNFC 9504, CNFC 95-6, VC-3, CNFC 10722, CVIII-119-4, CNFC 9500, sendo a cultivar Pérola, a testemunha. Foram avaliados o número de vagens por planta, número de grãos por vagem, massa de 100 grãos e produtividade. Para as características número de vagens por planta e número de grãos por vagem não foi observado diferença significativa entre os genótipos avaliados. Para a massa de 100 grãos os genótipos VC-16, BRSMG Majestoso, Pérola, CVIII-39-24, BP-31, MAII-16, RP-2, RP-1, CVIII-119-4, VC-15, MAII-2, apresentaram as maiores médias, sendo superiores a 22g. Os genótipos que obtiveram as melhores produtividades (kg ha-1) foram RP-2, BRS Cometa, BRS 9461, VC-3, BP-31, CVIII-85-11, BRSMG Majestoso, VC-16, BRSMG Talismã, VC-13, BRSMG Pioneiro, CNFC 10764, RP-1, CNFC 10722, VC-15, CVIII-119-4, Pérola, CNFC 9506, VC-14, CNFC 10720, CNFC 9503, CNFC 9500, no entanto, não houve diferença em relação a testemunha Pérola

Visuomotor learning promotes visually evoked activity in the medial prefrontal cortex

The medial prefrontal cortex (mPFC) is necessary for executing many learned associations between stimuli and movement. It is unclear, however, how activity in the mPFC evolves across learning, and how this activity correlates with sensory stimuli and the learned movements they evoke. To address these questions, we record cortical activity with widefield calcium imaging while mice learned to associate a visual stimulus with a forelimb movement. After learning, the mPFC shows stimulus-evoked activity both during task performance and during passive viewing, when the stimulus evokes no action. This stimulus-evoked activity closely tracks behavioral performance across training, with both exhibiting a marked increase between days when mice first learn the task, followed by a steady increase with further training. Electrophysiological recordings localized this activity to the secondary motor and anterior cingulate cortex. We conclude that learning a visuomotor task promotes a route for visual information to reach the prefrontal cortex

Multi-moment maps

We introduce a notion of moment map adapted to actions of Lie groups that preserve a closed three-form. We show existence of our multi-moment maps in many circumstances, including mild topological assumptions on the underlying manifold. Such maps are also shown to exist for all groups whose second and third Lie algebra Betti numbers are zero. We show that these form a special class of solvable Lie groups and provide a structural characterisation. We provide many examples of multi-moment maps for different geometries and use them to describe manifolds with holonomy contained in G_2 preserved by a two-torus symmetry in terms of tri-symplectic geometry of four-manifolds.Comment: 27 page

Randomized-controlled trial of the DIALIVE liver dialysis device vs. standard of care in patients with acute-on-chronic liver failure

BACKGROUND AND AIMS: Acute on chronic liver failure (ACLF) is characterized by severe systemic inflammation, multi-organ failure and high mortality rates. Its treatment is an urgent unmet need. DIALIVE is a novel liver dialysis device that aims to exchange d ysfunctional albumin and remove damage- and pathogen-associated molecular patterns. This first-in-man randomized, controlled clinical trial was performed with the primary aim of assessing its safety in ACLF patients with secondary aims to evaluate its clinical effects, device performance and effect on pathophysiologically-relevant biomarkers. METHODS: 32 alcoholic cirrhosis patients with ACLF were included. Patients were treated with DIALIVE for up to 5-days and end points were assessed at Day-10. Safety was assessed in all patients (n=32). The secondary aims were assessed in a pre-specified subgroup that had at least 3-treatment sessions with DIALIVE (n=30). RESULTS: There were no significant differences in 28-day mortality or occurrence of serious adverse events between the groups. Significant reduction in the severity of endotoxemia and improvement in albumin function was observed in DIALIVE group, which translated into a significant reduction in the CLIF-C (Chronic Liver Failure consortium) organ failure (p=0.018) and CLIF-C ACLF scores (p=0.042) at Day-10. Time to resolution of ACLF was significantly faster in DIALIVE group (p=0.036). Biomarkers of systemic inflammation such as IL-8 (p=0.006), cell death [cytokeratin-18: M30 (p=0.005) and M65 (p=0.029)], endothelial function [asymmetric dimethylarginine (p=0.002)] and, ligands for toll-like receptor 4 (p=0.030) and inflammasome (p=0.002) improved significantly in DIALIVE group. CONCLUSIONS: These data indicate that DIALIVE appears to be safe and impacts positively on prognostic scores and pathophysiologically relevant biomarkers in patients with ACLF. Larger, adequately powered studies are warranted to further confirm its safety and efficacy. LAY SUMMARY: This is the first-in-man clinical trial which tested DIALIVE, a novel liver dialysis device for the treatment of liver cirrhosis and acute on chronic liver failure, a condition associated with severe inflammation, organ failures and a high risk of death. The study met the primary end point confirming DIALIVE system to be safe. Additionally, it reduced inflammation with improved clinical parameters. It did not, however, reduce mortality in this small study and requires further larger clinical trials to re-confirm its safety and evaluate efficacy. CLINICAL TRIAL NUMBER: NCT03065699

The Malaria Testing and Treatment Market in Kinshasa, Democratic Republic of the Congo, 2013

Background The Democratic Republic of Congo (DRC) is one of the two most leading contributors to the global burden of disease due to malaria. This paper describes the malaria testing and treatment market in the nation’s capital province of Kinshasa, including availability of malaria testing and treatment and relative anti-malarial market share for the public and private sector. Methods A malaria medicine outlet survey was conducted in Kinshasa province in 2013. Stratified multi-staged sampling was used to select areas for the survey. Within sampled areas, all outlets with the potential to sell or distribute anti-malarials in the public and private sector were screened for eligibility. Among outlets with anti-malarials or malaria rapid diagnostic tests (RDT) in stock, a full audit of all available products was conducted. Information collected included product information (e.g. active ingredients, brand name), amount reportedly distributed to patients in the past week, and retail price. Results In total, 3364 outlets were screened for inclusion across Kinshasa and 1118 outlets were eligible for the study. Among all screened outlets in the private sector only about one in ten (12.1%) were stocking quality-assured Artemisinin-based Combination Therapy (ACT) medicines. Among all screened public sector facilities, 24.5% had both confirmatory testing and quality-assured ACT available, and 20.2% had sulfadoxine-pyrimethamine (SP) available for intermittent preventive therapy during pregnancy (IPTp). The private sector distributed the majority of anti-malarials in Kinshasa (96.7%), typically through drug stores (89.1% of the total anti-malarial market). Non-artemisinin therapies were the most commonly distributed anti-malarial (50.1% of the total market), followed by non quality-assured ACT medicines (38.5%). The median price of an adult quality-assured ACT was $6.59, and more expensive than non quality-assured ACT ($3.71) and SP ($0.44). Confirmatory testing was largely not available in the private sector (1.1%). Conclusions While the vast majority of anti-malarial medicines distributed to patients in Kinshasa province are sold within the private sector, availability of malaria testing and appropriate treatment for malaria is alarmingly low. There is a critical need to improve access to confirmatory testing and quality-assured ACT in the private sector. Widespread availability and distribution of non quality-assured ACT and non-artemisinin therapies must be addressed to ensure effective malaria case management

Recommendations and guidelines from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 1 -- In vivo small-animal imaging

The value of in vivo preclinical diffusion MRI (dMRI) is substantial. Small-animal dMRI has been used for methodological development and validation, characterizing the biological basis of diffusion phenomena, and comparative anatomy. Many of the influential works in this field were first performed in small animals or ex vivo samples. The steps from animal setup and monitoring, to acquisition, analysis, and interpretation are complex, with many decisions that may ultimately affect what questions can be answered using the data. This work aims to serve as a reference, presenting selected recommendations and guidelines from the diffusion community, on best practices for preclinical dMRI of in vivo animals. In each section, we also highlight areas for which no guidelines exist (and why), and where future work should focus. We first describe the value that small animal imaging adds to the field of dMRI, followed by general considerations and foundational knowledge that must be considered when designing experiments. We briefly describe differences in animal species and disease models and discuss how they are appropriate for different studies. We then give guidelines for in vivo acquisition protocols, including decisions on hardware, animal preparation, imaging sequences and data processing, including pre-processing, model-fitting, and tractography. Finally, we provide an online resource which lists publicly available preclinical dMRI datasets and software packages, to promote responsible and reproducible research. An overarching goal herein is to enhance the rigor and reproducibility of small animal dMRI acquisitions and analyses, and thereby advance biomedical knowledge.Comment: 69 pages, 6 figures, 1 tabl